GlassScriptPhysician profile
Andrew Day
NPI 1982167060
$3,219.43
in general payments reported to CMS, 2019-2025
15 companies · $2,979 in 2025
The $2,979 reported for 2025 was more than what 79% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $240 · 2025: $2,979.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,617 · Consulting Fee: $1,525 · Education: $76.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,617.44 |
| Consulting Fee | $1,525.00 |
| Education | $76.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,849.83 | 2025 | |
| Abbvie INC. | $670.24 | 2024-2025 | |
| Janssen Biotech, INC. | $161.68 | 2025 | |
| Argenx US, INC. | $126.71 | 2024-2025 | Vyvgart, Vyvgart Hytrulo |
| Neurocrine Biosciences, INC. | $83.86 | 2024-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $54.33 | 2024-2025 | Austedo Xr, Ajovy, Austedo Xr |
| Merz Pharmaceuticals, LLC | $43.82 | 2024 | Xeomin |
| Alexion Pharmaceuticals, INC. | $39.26 | 2024 | Ultomiris |
| Globus Medical, INC. | $34.89 | 2025 | Senza |
| Lundbeck LLC | $32.03 | 2025 | Vyepti |
| Axsome Therapeutics, INC. | $31.11 | 2025 | Symbravo |
| Medtronic, INC. | $29.58 | 2025 | Inceptiv |
| Grifols USA, LLC | $21.64 | 2025 | Gamunex-C |
| Boston Scientific Corporation | $21.49 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $18.96 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Day listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.